The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Costs and Cost Analysis

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Costs and Cost Analysis


Psychiatry related information on Costs and Cost Analysis


High impact information on Costs and Cost Analysis

  • A cost analysis of the lead-testing program in Orange County was conducted [8].
  • CONCLUSIONS: This cost analysis indicates that, regardless of the secondary treatment used for ulcer recurrence, initial therapy with antibiotics for H. pylori infection plus an H2-receptor antagonist provides the lowest costs per symptomatic cure [9].
  • Cost analysis may favor the use of one agent over another depending on the emetogenic challenge, dose of the 5-HT3 antagonists, and number of doses recommended [10].
  • Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis [11].
  • The use of alternative medical therapy may be a marker for care-seeking behavior associated with higher consumption of conventional medical resources in the absence of demonstrable additional morbidity and should be considered in future cost analyses of patients with SLE [12].

Chemical compound and disease context of Costs and Cost Analysis


Biological context of Costs and Cost Analysis


Anatomical context of Costs and Cost Analysis

  • A cost analysis of a testing strategy that used either total T4, free T4 index, or sensitive thyrotropin assay alone as the first-line thyroid test disclosed that to establish the patient's thyroid metabolic status would have cost $11,093, $14,536, and $24,902, respectively, using each test first [20].

Associations of Costs and Cost Analysis with chemical compounds


Gene context of Costs and Cost Analysis

  • DESIGN AND SETTING: The main analytical framework of the study was a cost-cost analysis comparing the total annual costs associated with the administration of etanercept and infliximab in adult RA patients [26].
  • However, several modeled cost analyses have suggested that COX-2 inhibitors are cost effective in subsets of patients because they are associated with fewer downstream costs, particularly medical and surgical treatment of gastrointestinal adverse effects [27].
  • Cost analysis of screening with prealbumin level projected a saving of $414 per patient screened [28].
  • A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion [29].
  • MAIN OUTCOME MEASURES: 1) Diagnostic yields of GJB2 screens, imaging, and laboratory results per SNHL category; 2) Cost analysis comparing a sequential versus a simultaneous testing approach [30].

Analytical, diagnostic and therapeutic context of Costs and Cost Analysis


  1. Clinical value of acute rest technetium-99m tetrofosmin tomographic myocardial perfusion imaging in patients with acute chest pain and nondiagnostic electrocardiograms. Heller, G.V., Stowers, S.A., Hendel, R.C., Herman, S.D., Daher, E., Ahlberg, A.W., Baron, J.M., Mendes de Leon, C.F., Rizzo, J.A., Wackers, F.J. J. Am. Coll. Cardiol. (1998) [Pubmed]
  2. Cost-analysis of high-dose chemotherapy and peripheral blood stem-cell support in patients with solid tumors. Astier, M.P., Mayordomo, J.I., Abad, J.M., Gómez, L.I., Tres, A. Ann. Oncol. (2000) [Pubmed]
  3. An economic cost analysis of oral ganciclovir prophylaxis for the prevention of CMV disease. Liu, G.G., Hay, J. Pharm. Res. (2000) [Pubmed]
  4. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Schiller, J., Tilden, D., Aristides, M., Lees, M., Kielhorn, A., Maniadakis, N., Bhalla, S. Lung Cancer (2004) [Pubmed]
  5. A comparison of methotrexate versus laparoscopic surgery for the treatment of ectopic pregnancy: a cost analysis. Yao, M., Tulandi, T., Kaplow, M., Smith, A.P. Hum. Reprod. (1996) [Pubmed]
  6. Research cost analyses to aid in decision making in the conduct of a large prevention trial, CARET. Carotene and Retinol Efficacy Trial. Thornquist, M.D., Urban, N., Tseng, A., Edelstein, C., Lund, B., Omenn, G.S. Controlled clinical trials. (1993) [Pubmed]
  7. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Wimo, A., Winblad, B., Stöffler, A., Wirth, Y., Möbius, H.J. PharmacoEconomics. (2003) [Pubmed]
  8. Lead poisoning among low-income children in Orange County, California. A need for regionally differentiated policy. Gellert, G.A., Wagner, G.A., Maxwell, R.M., Moore, D., Foster, L. JAMA (1993) [Pubmed]
  9. A cost analysis of alternative treatments for duodenal ulcer. Imperiale, T.F., Speroff, T., Cebul, R.D., McCullough, A.J. Ann. Intern. Med. (1995) [Pubmed]
  10. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis. Perez, E.A. J. Clin. Oncol. (1995) [Pubmed]
  11. Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis. Aletaha, D., Smolen, J.S. Arthritis Rheum. (2002) [Pubmed]
  12. The use of alternative medical therapies in patients with systemic lupus erythematosus. Trination Study Group. Moore, A.D., Petri, M.A., Manzi, S., Isenberg, D.A., Gordon, C., Senécal, J.L., St Pierre, Y., Joseph, L., Penrod, J., Fortin, P.R., Sutcliffe, N., Goulet, J.R., Choquette, D., Grodzicky, T., Esdaile, J.M., Clarke, A.E. Arthritis Rheum. (2000) [Pubmed]
  13. Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections. Davis, R., Balfour, J.A. PharmacoEconomics. (1995) [Pubmed]
  14. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia. Bucaneve, G., Menichetti, F., Del Favero, A. PharmacoEconomics. (1999) [Pubmed]
  15. A cost analysis of approved antiretroviral strategies in persons with advanced human immunodeficiency virus disease and zidovudine intolerance. Bozzette, S.A., Parker, R., Hay, J. J. Acquir. Immune Defic. Syndr. (1994) [Pubmed]
  16. Amiodarone and rural emergency medical services cardiac arrest patients: a cost analysis. Pazdral, T.E., Burton, J.H., Strout, T.D., Bradshaw, J.R. Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors. (2002) [Pubmed]
  17. A comparison of nisoldipine ER and amlodipine for the treatment of mild to moderate hypertension. Whitcomb, C., Enzmann, G., Pershadsingh, H.A., Johnson, R., Ciuryla, V., Reisin, E. International journal of clinical practice. (2000) [Pubmed]
  18. A cost analysis of participation via personal attendance versus telemedicine at a head and neck oncology multidisciplinary team meeting. Stalfors, J., Björholt, I., Westin, T. Journal of telemedicine and telecare. (2005) [Pubmed]
  19. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). Gray, A., Clarke, P., Farmer, A., Holman, R. BMJ (2002) [Pubmed]
  20. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. de los Santos, E.T., Starich, G.H., Mazzaferri, E.L. Arch. Intern. Med. (1989) [Pubmed]
  21. Conceptual and cost analysis errors in the evaluation of bedside capillary glucose testing. Haas, S.N. Am. J. Med. (1995) [Pubmed]
  22. Lack of clinical utility of folate levels in the evaluation of macrocytosis or anemia. Robinson, A.R., Mladenovic, J. Am. J. Med. (2001) [Pubmed]
  23. Low-dose dapsone prophylaxis of Pneumocystis carinii pneumonia in AIDS and AIDS-related complex. Kemper, C.A., Tucker, R.M., Lang, O.S., Kessinger, J.M., Greene, S.I., Deresinski, S.C., Stevens, D.A. AIDS (1990) [Pubmed]
  24. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis. Schwartz, S., Sievers, R., Strange, P., Lyness, W.H., Hollander, P. Diabetes Care (2003) [Pubmed]
  25. Comments on cost analysis of risperidone versus olanzapine. Duggal, H.S., Gandotra, G. The Journal of clinical psychiatry. (2004) [Pubmed]
  26. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Nuijten, M.J., Engelfriet, P., Duijn, K., Bruijn, G., Wierz, D., Koopmanschap, M. PharmacoEconomics. (2001) [Pubmed]
  27. Pharmacoeconomics of coxib therapy. Cantor, S.B. Journal of pain and symptom management. (2002) [Pubmed]
  28. Prealbumin measurement as a screening tool for protein calorie malnutrition in emergency hospital admissions: a pilot study. Potter, M.A., Luxton, G. Clinical and investigative medicine. Médecine clinique et experimentale. (1999) [Pubmed]
  29. A cost analysis of bone morphogenetic protein versus autogenous iliac crest bone graft in single-level anterior lumbar fusion. Polly, D.W., Ackerman, S.J., Shaffrey, C.I., Ogilvie, J.W., Wang, J.C., Stralka, S.W., Mafilios, M.S., Heim, S.E., Sandhu, H.S. Orthopedics. (2003) [Pubmed]
  30. Improved diagnostic effectiveness with a sequential diagnostic paradigm in idiopathic pediatric sensorineural hearing loss. Preciado, D.A., Lawson, L., Madden, C., Myer, D., Ngo, C., Bradshaw, J.K., Choo, D.I., Greinwald, J.H. Otol. Neurotol. (2005) [Pubmed]
  31. A cost analysis of enterally administered lorazepam in the pediatric intensive care unit. Lugo, R.A., Chester, E.A., Cash, J., Grant, M.J., Vernon, D.D. Crit. Care Med. (1999) [Pubmed]
  32. Is cytology required for a hematuria evaluation? Hofland, C.A., Mariani, A.J. J. Urol. (2004) [Pubmed]
  33. Percutaneous ethanol injection vs. resection in patients with small single hepatocellular carcinoma: a retrospective case-control study with cost analysis. Gournay, J., Tchuenbou, J., Richou, C., Masliah, C., Lerat, F., Dupas, B., Martin, T., Nouel, J.F., Schnée, M., Montigny, P., D'Alincourt, A., Hamy, A., Paineau, J., Le Néel, J.C., Le Borgne, J., Galmiche, J.P. Aliment. Pharmacol. Ther. (2002) [Pubmed]
  34. A cost analysis of nalbuphine versus meperidine used in oral surgery procedures. Rhodes, R.A. Clinical therapeutics. (1986) [Pubmed]
  35. A cost analysis of the prevention of end-stage renal disease: immunoglobulin therapy for IgA nephropathy. Durand-Zaleski, I., Bastuji-Garin, S., Zaleski, S., Weil, B., Rostoker, G. Medical decision making : an international journal of the Society for Medical Decision Making. (1996) [Pubmed]
WikiGenes - Universities